Literature DB >> 11013358

Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma.

M Shiba1, H Kohno, K Kakizawa, T Iizasa, M Otsuji, Y Saitoh, K Hiroshima, H Ohwada, T Fujisawa.   

Abstract

BACKGROUND: To estimate the effectiveness of expression of the tumor proliferative marker Ki-67 antigen (Ki-67) as a postoperative prognostic marker, the authors analyzed Ki-67 expression and its correlation with postoperative survival and other clinicopathologic factors, including preoperative smoking habits, in patients with resected nonsmall cell lung carcinoma (NSCLC).
METHODS: A total of 156 patients with resected NSCLC at the study institution were investigated. Postoperative survival rates were estimated based on demographic and clinicopathologic factors, including Ki-67 expression and preoperative tobacco smoking habits.
RESULTS: The overall postoperative 5-year survival rate in patients with high Ki-67 labeling indices (>/= 20%) was 39.6% compared with 67.7% in patients with low Ki-67 labeling indices. This finding was significant for all resected cases and for each pathologic disease stage (P < 0.05). The postoperative 5-year survival rate in patients with a history of heavy smoking (>/= 30 pack-years) was 47.6% compared with 62.5% for other patients (P = 0.027). This result was especially significant in patients with International Union Against Cancer Stage I disease and in patients with nonsquamous cell carcinoma (P < 0.03). The authors also observed a positive correlation between the Ki-67 labeling index and preoperative smoking habits (P = 0.0002). Multivariate analysis demonstrated that lymph node involvement, tumor differentiation, and Ki-67 labeling index were significant prognostic factors in NSCLC (P < 0.01).
CONCLUSIONS: Tumor Ki-67 expression is a strong prognostic factor in NSCLC, especially adenocarcinoma. It may be hypothesized that tobacco mutagenicity may play a role in the growth and extension of NSCLC, which is one of the major impediments to postoperative survival in patients with a history of heavy smoking.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11013358     DOI: 10.1002/1097-0142(20001001)89:7<1457::aid-cncr7>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Prognostic role of p53 and Ki-67 immunohistochemical expression in patients with surgically resected lung adenocarcinoma: a retrospective study.

Authors:  Cheol-Hong Kim; Hee Sung Lee; Ju-Hee Park; Jeong-Hee Choi; Seung-Hun Jang; Yong-Bum Park; Myung Goo Lee; In Gyu Hyun; Kun Il Kim; Hyoung Soo Kim; Sung Woo Cho; Won Yong Lee; Eung-Joong Kim; Haeyoung Kim; Jung Weon Shim; Young Hee Choi
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

2.  Impact of postdiagnosis smoking on long-term survival of cancer patients: the Shanghai cohort study.

Authors:  Li Tao; Renwei Wang; Yu-Tang Gao; Jian-Min Yuan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12       Impact factor: 4.254

3.  Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.

Authors:  Jhanelle E Gray; Soner Altiok; Mark G Alexandrow; Frank W Walsh; Jian Chen; Michael J Schell; Datchen Fritz Tai; Gerold Bepler
Journal:  Cancer       Date:  2012-10-12       Impact factor: 6.860

4.  Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters.

Authors:  Marianna Grinberg; Dijana Djureinovic; Hans Rr Brunnström; Johanna Sm Mattsson; Karolina Edlund; Jan G Hengstler; Linnea La Fleur; Simon Ekman; Hirsh Koyi; Eva Branden; Elisabeth Ståhle; Karin Jirström; Derek K Tracy; Fredrik Pontén; Johan Botling; Jörg Rahnenführer; Patrick Micke
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

5.  Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma.

Authors:  Feng Jiang; Xuepeng Zhang; Steven N Kalkanis; Zhenggang Zhang; Hongyan Yang; Mark Katakowski; Xin Hong; Xuguang Zheng; Zhenping Zhu; Michael Chopp
Journal:  Photochem Photobiol       Date:  2008 Jan-Feb       Impact factor: 3.421

6.  Proliferation PET image to characterize pathological spatial features in patients with non-small cell lung cancer: a pilot study.

Authors:  Xiao-Ting Chen; Xin Zhao; Zhen-Hua Gao; Yong-Sheng Gao; Bai-Jiang Zhang; Zheng Fu; Dian-Bin Mu; Jin-Ming Yu; Xue Meng
Journal:  Int J Clin Exp Med       Date:  2015-06-15

7.  Post-acute response of 9L gliosarcoma to Photofrin-mediated PDT in athymic nude mice.

Authors:  Xuepeng Zhang; Feng Jiang; Steven N Kalkanis; ZhengGang Zhang; Xin Hong; Hongyan Yang; Michael Chopp
Journal:  Lasers Med Sci       Date:  2007-02-15       Impact factor: 3.161

Review 8.  Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis.

Authors:  A Parsons; A Daley; R Begh; P Aveyard
Journal:  BMJ       Date:  2010-01-21

9.  Chemopreventive effects of pterostilbene through p53 and cell cycle in mouse lung of squamous cell carcinoma model.

Authors:  Omchit Surien; Ahmad Rohi Ghazali; Siti Fathiah Masre
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

10.  Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.

Authors:  Matthias Scheffler; Thomas Zander; Lucia Nogova; Carsten Kobe; Deniz Kahraman; Markus Dietlein; Irini Papachristou; Lukas Heukamp; Reinhard Büttner; Ron Boellaard; Adriaan A Lammertsma; Silvia Querings; Erich Stoelben; Walburga Engel-Riedel; Bernd Neumaier; Jürgen Wolf
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.